Pascal Piedbois
About Pascal Piedbois
Pascal Piedbois is the Senior Vice President, Medical Head Major Markets at Bristol Myers Squibb, with extensive experience in oncology and infection.
Company
Pascal Piedbois currently works at Bristol Myers Squibb, holding the title of Senior Vice President, Medical Head Major Markets. His role involves overseeing medical strategies and operations in major markets. Previously, he has been associated with various major pharmaceutical companies, including Boehringer Ingelheim and AstraZeneca, in significant leadership roles.
Title
Pascal Piedbois serves as the Senior Vice President, Medical Head Major Markets, at Bristol Myers Squibb. His responsibilities include leading medical operations and strategies across major markets, ensuring effective implementation of plans and overseeing medical directors.
Education and Expertise
Pascal Piedbois studied at Paris University, attaining an MD and PhD, and served as a Professor of Medicine. He has significant expertise in oncology and infection, having served as Vice President Global Medical Affairs Oncology and Infection at AstraZeneca. His academic contributions include a decade of teaching oncology at Henri Mondor Hospital, Paris University.
Professional Background
Pascal Piedbois has a robust professional background with experience in notable roles. He was previously a Medical Director at Bristol Myers Squibb in Paris. At Boehringer Ingelheim, he served as General Manager in Belgium and Head Medicine France. He also held the position of General Manager at Paul Strauss Cancer Center & Alsace Regional Cancer Institute, focusing on cancer treatment and management. At AstraZeneca, he served as Vice President Global Medical Affairs Oncology and Infection and as Medical Director in France.
Achievements in Oncology
Pascal Piedbois has an extensive background in oncology, demonstrated through his roles at AstraZeneca and significant academic experience. As Vice President Global Medical Affairs Oncology and Infection at AstraZeneca, he contributed to the company's medical strategies in these critical therapeutic areas. Additionally, he dedicated a decade to teaching oncology at Paris University, specifically at Henri Mondor Hospital.